Merck’s fourth-quarter results top estimates, fueled by key cancer drugs and vaccines
MarketWatch
Merck on Thursday reported fourth-quarter earnings and sales that beat analyst expectations, powered by strong growth in cancer and vaccine products.
Continue Reading